The Truth Behind Weight-Loss Drugs: Hype or Hope?

Analyst Andrew Charles of TD Cowen believes that weight-loss drugs like Ozempic or Wegovy, despite being named Novo Nordisk's Company of the Year, will have a limited long-term impact on calorie reduction and overall population health. TD Cowen's outlook for GLP-1s predicts 14.3 million people in the US taking the drugs, resulting in a 30% reduction in calories by users and a 0.07% decrease in overall US population calorie consumption. Charles suggests that stocks like Domino's Pizza, Wingstop, and Darden Restaurants may be more protected from the potential impact of weight-loss drugs due to their focus on delivery and dining out occasions.